Emerging Stocks Down Under 19 October 2021: Chimeric Therapeutics, Adslot, Memphasys

Chimeric Therapeutics: Put this one in your basket

In today's edition of Emerging Stocks Down Under, Chimeric Therapeutics is a Melbourne-based biotechnology company currently developing T-cell therapy drugs to combat cancer. Despite being extremely young (incorporated in 2020), the company recently entered the clinical stage and is rapidly developing its CLTX-CAR T-cell therapies that could potentially be used to treat a variety of cancers. With its successful IPO, the company may be able to commence further trials to test its therapies against various cancers.   Also in today's edition, a look at developer of the Adslot platform, Adslot (ASX: ADS) and biomedical device developer Memphasys (ASX: MEM).  

Click here to read the previous edition of Emerging Stocks Down Under published 12 October 2021

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.

Please register or upgrade your plan to access this content.

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks